Trial Profile
An investigation of effect and safety of Apatinib in the treatment of advanced NSCLC
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 22 Nov 2017 New trial record